[ Double - blind placebo - controlled study of the <font color="red">effectiveness_5</font> <font color="red">and_4</font> <font color="red">tolerability_5</font> <font color="red">of_1</font> <font color="red">10_1</font> <font color="red">and_1</font> <font color="red">30_1</font> <font color="red">mg_1</font> <font color="red">ketorolac_1</font> tromethamine suppositories in <font color="red">post_2</font> <font color="red">-_2</font> <font color="red">cholecystectomy_2</font> <font color="red">pain_2</font> <font color="red">]_2</font> . 
<br>
<br> OBJECTIVE To evaluate the efficacy and tolerability of ketorolac tromethamine 10 mg and 30 mg suppositories in comparison to placebo , after single dose administration in patients suffering from <font color="red">post_1</font> <font color="red">-_1</font> <font color="red">operative_1</font> <font color="red">pain_1</font> after cholecystectomy . 
<br> DESIGN Double - blind , randomized , controlled study . 
<br> SETTING Anaesthesia Service . 
<br> PATIENTS 99 patients with severe pain following surgery . 
<br> INTERVENTIONS Cholecystectomy . 
<br> MEASUREMENTS AND MAIN RESULTS The <font color="red">analgesia_1</font> activity of ketorolac tromethamine 10 mg and 30 mg suppositories were evaluated after single dose administration by assessing <font color="red">pain_4</font> <font color="red">intensity_4</font> <font color="red">and_4</font> <font color="red">pain_4</font> <font color="red">relief_4</font> <font color="red">using_1</font> <font color="red">a_1</font> <font color="red">4_2</font> <font color="red">point_2</font> <font color="red">scale_2</font> <font color="red">(_2</font> <font color="red">VRS_2</font> <font color="red">)_2</font> <font color="red">._2</font> At the end of the treatment period <font color="red">overall_1</font> <font color="red">assessment_1</font> <font color="red">of_1</font> <font color="red">safety_4</font> <font color="red">and_4</font> <font color="red">efficacy_4</font> <font color="red">were_1</font> <font color="red">recorded_1</font> <font color="red">by_1</font> <font color="red">physician_1</font> <font color="red">and_1</font> <font color="red">patient_1</font> <font color="red">._1</font> The results show that in both active groups after 30 ' and until 4 hours , <font color="red">pain_5</font> <font color="red">intensity_4</font> <font color="red">decreased_1</font> significantly with respect to the baseline . However a statistically significant difference between groups of p < 0.02 , p < 0.01 and p < 0.05 was found in favour of the 30 mg dose respectively at 30 ' , 6 and 8 hours after administration . All the patients treated with placebo suppositories required another <font color="red">rescue_1</font> <font color="red">analgesic_1</font> <font color="red">drug_1</font> and <font color="red">withdrew_1</font> <font color="red">from_1</font> <font color="red">the_1</font> <font color="red">trial_1</font> <font color="red">._1</font> Three patients <font color="red">complained_1</font> <font color="red">adverse_3</font> <font color="red">events_3</font> not related to treatment : two on placebo and one on ketorolac 10 mg . The <font color="red">systemic_1</font> <font color="red">and_1</font> <font color="red">local_1</font> <font color="red">tolerability_1</font> of the drug was good . 
<br> CONCLUSIONS This study shows that <font color="red">ketorolac_1</font> <font color="red">30_1</font> <font color="red">mg_1</font> <font color="red">suppositories_1</font> <font color="red">are_1</font> <font color="red">effective_1</font> <font color="red">in_1</font> <font color="red">clinical_1</font> <font color="red">conditions_1</font> <font color="red">,_1</font> such as after surgery , in which <font color="red">pain_1</font> <font color="red">control_1</font> must be achieved within the shortest time interval and maintained or improved by means of a single route of administration .